Skip to main content



13-01-2022 | Paediatrics | News | Article

Novel loci affect asthma treatment response in children of African descent

Researchers identify novel loci that may contribute to the success of asthma treatment in children of African descent, but find these differ between adolescents and younger children.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

27-10-2021 | Oncology | News | Article

Pathogenic mismatch repair variants IMPACT prostate cancer incidence

Men who carry germline mismatch repair pathogenic variants in the MSH2 and MSH6 genes, typically associated with Lynch syndrome, have a significantly higher incidence of prostate cancer than noncarriers, show early data from the IMPACT study.

13-04-2021 | Oncology | News | Article

Mechanisms of resistance to KRAS G12C inhibition characterized

US researchers have identified diverse molecular and histologic mechanisms of acquired resistance to KRAS G12C inhibitors in people with cancer.

25-02-2021 | Oncology | News | Article

CDKN2A alterations may predict ICI outcomes in metastatic urothelial cancer

Genomic alterations in CDKN2A are associated with worse clinical outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors, report US researchers.

16-12-2020 | Oncology | News | Article

Integrated tool may individualize prognosis prediction in early breast cancer

A prognostic tool that integrates clinicopathologic and genomic data provides more information on distant recurrence risk than either feature alone, and can estimate absolute chemotherapy benefit in individual patients with node-negative breast cancer, say researchers.

21-10-2020 | Oncology | News | Article

Gene-based model may identify high-risk breast cancer patients

A prognostic model based on eight DNA repair-related genes may help identify women with breast cancer who are at high risk for death, Chinese researchers report.

11-09-2020 | Oncology | News | Article

FDA approves liquid biopsy test for somatic, germline mutations

Click through to read more

19-08-2020 | Oncology | News | Article

FDA approves liquid biopsy NGS technology

Read more on this announcement here

02-07-2020 | Oncology | News | Article

Support for ‘plasma-first’ approach in molecular testing for NSCLC

Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.

29-06-2020 | Oncology | News | Article

Entrectinib receives positive decision from EMA

More details about the announcement are a click away

01-05-2020 | Oncology | News | Article

Larotrectinib response best with NTRK fusion mutations

Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.

15-04-2020 | Oncology | News | Article

Long noncoding RNA signatures may help predict immunotherapy response

Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.

13-11-2019 | Oncology | News | Article

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

15-10-2019 | Oncology | News | Article

Value of blood-based screening for ALK fusions shown in patients with NSCLC

Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

10-10-2019 | Oncology | News | Article

PROfound paves the way for precision medicine in mCRPC

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

08-07-2019 | Rheumatology | News | Article

RA genetic risk linked to IQ, hyperactivity during childhood

Genetic liability for rheumatoid arthritis is associated with lower IQ and symptoms of hyperactivity and inattention during childhood and adolescence, supporting a link between genetic risk for the condition and neural phenotypes, UK researchers report.

22-01-2019 | Oncology | News | Article

Mutational load predicts immunotherapy response across most tumor types

Tumor mutational burden could be a cross-tumor predictive biomarker of immunotherapy, say US researchers who found an association between mutational load and survival across a wide range of malignancies treated with immune checkpoint inhibitors.

16-01-2019 | Prostate cancer | News | Article

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

11-01-2019 | Oncology | News | Article

COMT gene modifies chemopreventive effects of vitamin E

Vitamin E supplementation may reduce the risk for cancer but only in individuals harboring a particular allele of the catechol-O-methyltransferase gene, suggests an analysis of two randomized trials.

20-12-2018 | Asthma | News | Article

Genetic variants linked to moderate-to-severe asthma susceptibility

A genome-wide association study has identified novel genetic variants associated with the risk of developing moderate-to-severe asthma, a substantial proportion of which are also associated with mild asthma susceptibility.